Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.

The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also provides Breath Biopsy products and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.

Onespacemedia were appointed to reimagine Owlstone Medical's marketing website to modernise this pioneering organisation's digital presence. Since the original commision we have worked under retainer to provide a range of design and technical solutions that are contributing to Owlstone Medical's marketing and business development mix. Our most recent project has seen the addition of an ecommerce platform to support a pivot in how the organisation provides research and diagnostic opportunities to its customers.